Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals Drug

Alteogen Licenses ALT‑B4 Hyaluronidase to Tesaro for $285M Subcutaneous Dostarlimab Deal

Fineline Cube Jan 22, 2026
Company Deals

Eyebright Medical to Acquire Control of Delta Medical in $143 M Sports‑Medicine Deal

Fineline Cube Jan 22, 2026
Company Deals

Insilico Licenses NLRP3 Inhibitor ISM8969 to Hengtai in $64M CNS Drug Deal

Fineline Cube Jan 20, 2026
Company Deals

Shionogi Boosts ViiV Stake to 21.7% in $2.1 Billion Deal, Doubles Down on HIV Focus

Fineline Cube Jan 20, 2026
Company Deals Medical Device

EasyDiagnosis Bio to Acquire 51% of Ailex Medical in $5.1M Deal, Gains IVD Platform

Fineline Cube Jan 20, 2026
Company Drug Policy / Regulatory

Merson’s Bemejing Wins First CNMR “Overseas Version” Drug Price Certificate

Fineline Cube Jan 21, 2026
Company Deals Drug

Alteogen Licenses ALT‑B4 Hyaluronidase to Tesaro for $285M Subcutaneous Dostarlimab Deal

Fineline Cube Jan 22, 2026
Company Drug

Shanghai Pharma’s iNKT Cell Therapy B023 Gets NMPA Nod for Advanced Solid Tumors

Fineline Cube Jan 22, 2026
Company Drug

Changchun High & New Technology Industries Receives NMPA Approval for Long-Acting Somatropin

Fineline Cube Nov 6, 2024

Changchun High & New Technology Industries (Group) Inc., (SHE: 000661), a leading China-based company, has...

Company Drug

Huadong Medicine Co., Ltd Receives NMPA Approval for Stelara Biosimilar SaiLeXin

Fineline Cube Nov 6, 2024

Huadong Medicine Co., Ltd (SHE: 000963), a China-based pharmaceutical company, has announced that it has...

Company Deals

Northeast Pharmaceutical to Acquire Majority Stake in Dingcheng Peptide Source for RMB 186.8 Million

Fineline Cube Nov 6, 2024

China-based Northeast Pharmaceutical Co., Ltd (SHE: 000597) has announced its intention to acquire a 70%...

Company Drug

Ascentage Pharma to Present Olverembatinib and Lisaftoclax Clinical Data at ASH Annual Meeting

Fineline Cube Nov 6, 2024

China-based Ascentage Pharma (HKG: 6855) has announced that it will present the results of multiple...

Company Drug

CStone Pharmaceuticals Presents CS5001 Clinical Data at the ASH Annual Meeting

Fineline Cube Nov 6, 2024

China-based CStone Pharmaceuticals (HKG: 2616) has announced the presentation of the latest clinical data on...

Company Drug

Roche to Showcase 40+ Abstracts on Blood Disorders at ASH Annual Meeting

Fineline Cube Nov 6, 2024

Swiss pharmaceutical giant Roche (SWX: ROG) has announced plans to present over 40 abstracts across...

Company Drug

China Medical System’s Opzelura Approved in Hong Kong for Non-segmental Vitiligo Treatment

Fineline Cube Nov 6, 2024

China Medical System Holdings (CMS; HKG: 0867) has announced that the market filing for its...

Company Drug

Legend Biotech to Showcase CARTITUDE-4 Trial Data on Carvykti at ASH Annual Meeting

Fineline Cube Nov 6, 2024

China-based Legend Biotech Corporation (NASDAQ: LEGN) is set to present new data on minimal residual...

Company Deals

Shanghai Duoning Biotechnology Partners with Branca Bunús for Transfection Reagents Innovation

Fineline Cube Nov 6, 2024

Shanghai Duoning Biotechnology Co., Ltd, a prominent biopharmaceutical company in China, has entered into a...

Policy / Regulatory

NMPA Draft Proposal Aims to Strengthen Supervision of Drug Entrusted Manufacturing

Fineline Cube Nov 6, 2024

The National Medical Products Administration (NMPA) has released a draft proposal titled “Announcement on Strengthening...

Company Drug

Asieris Pharmaceuticals Receives NMPA Approval for Hexvix (APL-1706) in Bladder Cancer Diagnosis

Fineline Cube Nov 6, 2024

China-based urogenital cancer specialist Asieris Pharmaceuticals (SHA: 688176) has announced that the National Medical Products...

Company Drug

Frontier Biotechnologies Inc. Gets NMPA Approval for Phase II Study of Albuvirtide as HIV Therapy

Fineline Cube Nov 6, 2024

Nanjing-based Frontier Biotechnologies Inc. (SHA: 688221) has received approval from the National Medical Products Administration...

Company

Fresenius Medical Care Reports 2% YOY Revenue Decrease in 2024 Q3 Financial Results

Fineline Cube Nov 6, 2024

Germany-based Fresenius Medical Care (FRA: FMEA) has released its financial report for the third quarter...

Company Deals

Beijing Mabworks Biotech’s IPO Application Accepted by Beijing Stock Exchange

Fineline Cube Nov 5, 2024

Beijing Mabworks Biotech Co., Ltd, a China-based biotech firm, has seen its initial public offering...

Company

Takeda Reports 5% YOY Revenue Growth and Upgrades Forecasts for Fiscal 2024

Fineline Cube Nov 5, 2024

Takeda (TYO: 4502) has released its earnings results for the first half of fiscal year...

Company Drug

Windtree Therapeutics Secures Hong Kong Patent for Istaroxime Heart Failure Treatment

Fineline Cube Nov 5, 2024

US biotechnology company Windtree Therapeutics, Inc. (NASDAQ: WINT) has announced the receipt of a patent...

Company Drug

BMS’s Opdivo Secures NMPA Approval for Urothelial Carcinoma Treatment

Fineline Cube Nov 5, 2024

Bristol Myers Squibb (BMS; NYSE: BMY) has announced that it has received another indication approval...

Company Deals

Boston Scientific Corporation Announces Acquisition of Cortex, Inc.

Fineline Cube Nov 5, 2024

US-based medical device giant Boston Scientific Corporation (NYSE: BSX) has entered into a definitive agreement...

Medical Device Policy / Regulatory

China’s NMPA Issues Guidelines for Domestic Manufacturing of Imported Medical Devices

Fineline Cube Nov 5, 2024

The National Medical Products Administration (NMPA) has released a notification aimed at further clarifying the...

Company

Legend Biotech Corporation Appoints Alan Bash as President of Carvykti

Fineline Cube Nov 5, 2024

China-based chimeric antigen receptor (CAR) T cell therapy specialist, Legend Biotech Corporation (NASDAQ: LEGN), has...

Posts pagination

1 … 218 219 220 … 612

Recent updates

  • Alteogen Licenses ALT‑B4 Hyaluronidase to Tesaro for $285M Subcutaneous Dostarlimab Deal
  • Shanghai Pharma’s iNKT Cell Therapy B023 Gets NMPA Nod for Advanced Solid Tumors
  • Biokin’s Iza-bren ADC Receives NMPA Filing Acceptance for ESCC, World’s First EGFR×HER3 Bispecific
  • Kawin Technology Withdraws Hepatitis B Filing for Peginterferon Alfacon‑2 After NMPA Feedback
  • Eyebright Medical to Acquire Control of Delta Medical in $143 M Sports‑Medicine Deal
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals Drug

Alteogen Licenses ALT‑B4 Hyaluronidase to Tesaro for $285M Subcutaneous Dostarlimab Deal

Company Drug

Shanghai Pharma’s iNKT Cell Therapy B023 Gets NMPA Nod for Advanced Solid Tumors

Company Drug

Biokin’s Iza-bren ADC Receives NMPA Filing Acceptance for ESCC, World’s First EGFR×HER3 Bispecific

Company Drug

Kawin Technology Withdraws Hepatitis B Filing for Peginterferon Alfacon‑2 After NMPA Feedback

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.